Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)

MLA

KVO Docenten, et al. Correction to: Exposure-Survival Analyses of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients: Opportunities for Dose Optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/S00280-017-3463-X). 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432112495&authtype=sso&custid=ns315887.

APA

KVO Docenten, Apotheek Onderzoek, Cancer, Externen Med. Onco, Verheijen, R. B., Swart, E. L., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R., & Steeghs, N. (2020). Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x).

Chicago

KVO Docenten, Apotheek Onderzoek, Cancer, Externen Med. Onco, R B Verheijen, E L Swart, J H Beijnen, J H M Schellens, A D R Huitema, and N Steeghs. 2020. “Correction to: Exposure-Survival Analyses of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients: Opportunities for Dose Optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/S00280-017-3463-X).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432112495&authtype=sso&custid=ns315887.